Skip to main content
. 2020 May 19;9:69. doi: 10.1186/s13756-020-00740-7

Table 2.

Analysis of risk factors for SSI in patients undergoing CS in the PRE-Int and POST-Int groups and Overall

Overall (n = 1040) PRE-Int (n = 467) POST-Int (n = 573)
SSI (n = 320) No SSI (n = 720) p-value SSI (n = 225) No SSI (n = 242) p-value SSI (n = 95) No SSI (n = 478) p-value
Age, years 0.403 0.561 0.009
  < 20 58 (35.2) 107 (64.8) 33 (43.4) 43 (56.6) 25 (28.1) 64 (71.9)
 21–34 220 (29.9) 516 (70.1) 164 (48.4) 175 (51.6) 56 (14.1) 341 (85.9)
  > 34 39 (29.8) 92 (70.2) 27 (52.9) 24 (47.1) 12 (15.0) 68 (85.0)
 Not known 1 (100) 0 2 (28.6) 5 (71.4)
BMI, median (range) 27.8 (14–46) 26.9 (16–66) 0.031 27.7 (19–46) 26.7 (18–45) 0.060 27.8 (14–41) 27 (16–66) 0.224
Education 0.327 0.518 0.621
 No 46 (35.1) 85 (64.9) 34 (51.5) 32 (48.5) 12 (18.5) 53 (81.5)
 Standard 7a 165 (31.2) 364 (68.8) 112 (46.5) 129 (53.5) 53 (18.4) 235 (81.6)
 Form I-VIb 88 (30.4) 201 (69.6) 68 (51.5) 64 (48.5) 20 (12.7) 137 (87.3)
 College/University 16 (21.1) 60 (78.9) 7 (33.3) 14 (66.7) 9 (16.4) 46 (83.6)
 Not known 5 (33.3) 10 (66.7) 4 (57.1) 3 (42.9) 1 (12.5) 7 (87.5)
HIV+ 0.097 0.462 0.104
 Yes 16 (44.4) 20 (55.6) 10 (58.8) 7 (41.2) 6 (31.6) 13 (68.4)
 No 295 (30.4) 676 (69.6) 211 (48.2) 227 (51.8) 84 (15.8) 449 (84.2)
 Not known 9 (27.3) 24 (72.7) 4 (33.3) 8 (66.7) 5 (23.8) 16 (76.2)
CS type 0.607 0.469 0.338
 Elective 21 (27.6) 55 (72.4) 18 (42.9) 24 (57.1) 3 (8.8) 31 (91.2)
 Emergency 299 (21.0) 665 (69.0) 207 (48.7) 218 (51.3) 92 (17.1) 447 (82.9)
Indication for CS 0.801 0.558 0.084
 Previously knownc 133 (30.8) 299 (69.2) 104 (49.5) 106 (50.5) 29 (13.1) 193 (86.9)
 Not previously known 187 (30.8) 420 (69.2) 121 (47.3) 135 (52.7) 66 (18.8) 285 (81.2)
Operator grade 0.006 0.038 1.000
 Junior 229 (33.4) 456 (66.6) 172 (51.0) 165 (49.0) 57 (16.4) 291 (83.6)
 Senior 87 (25.2) 258 (74.8) 51 (40.2) 76 (59.8) 36 (16.5) 182 (83.5)
Skin disinfection < 0.001 0.410 1.000
 Dettol/Ethanol 48 (50.0) 48 (50.0) 47 (52.2) 43 (47.8) 1 (16.7) 5 (83.3)
 Povidone-Iodine 265 (28.7) 658 (71.3) 172 (47.0) 194 (53.0) 93 (16.7) 464 (83.3)
Type of incision < 0.001 < 0.001 < 0.001
 Midline Vertical 280 (38.0) 457 (62.0) 198 (58.1) 143 (41.9) 82 (20.7) 152 (92.1)
Pfannenstiel 37 (15.0) 210 (85.0) 24 (29.3) 58 (70.7) 13 (7.9) 314 (79.3)
Skin suture < 0.001 0.370 0.006
 Silk 237 (34.2) 456 (65.8) 167 (49.3) 172 (50.7) 70 (19.8) 284 (80.2)
 Vicryl (absorbable) 58 (21.9) 207 (78.1) 40 (44.0) 51 (56.0) 18 (10.3) 156 (89.7)
Suture type < 0.001 < 0.001 < 0.001
 Interrupted 268 (38.3) 432 (61.7) 190 (58.1) 137 (41.9) 78 (20.9) 295 (79.1)
 Continuous intradermic and semisubcutaneous 45 (16.7) 225 (83.3) 31 (32.3) 65 (67.7) 14 (8.0) 160 (92.0)
Pre-Incision Prophylaxis < 0.001 1.000 1.000
 No 216 (47.3) 241 (52.7) 215 (47.7) 236 (52.3) 1 (16.7) 5 (83.3)
 Yes 97 (17.0) 475 (83.0) 5 (50.0) 5 (50.0) 92 (16.4) 470 (83.6)
Timing of pre-Incision Prophylaxis 0.548 0.428 0.307
 Adequate 25 (27.2) 137 (31) 3 (100) 2 (50) 22 (24.7) 135 (30.8)
 Not adequate 67 (72.8) 305 (69) 0 2 (50) 67 (75.3) 303 (69.2)
Post-CS ATB administration < 0.001 1.000 0.220
 No 64 (15.8) 342 (84.2) 2 (50.0) 2 (50.0) 62 (15.4) 340 (84.6)
 Yes 253 (40.4) 374 (59.6) 220 (47.9) 239 (52.1) 33 (19.6) 135 (80.4)

aPrimary education; bSecondary education; ccephalopelvic disproportion, bad obstetric history, previous CS